Potential near-and mid-term value drivers
- Sustained M&A & in-licensing to build critical mass in oncology
- Cantrixil – initiation of Phase 2
- Docetaxel micellar – Phase 1b completion
- Apealea® – initiation of additional US pivotal studies by Elevar; partnering in key territories; potential for initial royalties
- XR-17™ technology platform – enhancement
- Animal Health assets – divestment or partnering agreements
-
2 nd most common
Cancer is the 2nd most common cause of death1
-
18 million people
18 million people were diagnosed with cancer in 20181
-
USD 240 billion
The total expenditure on oncology worldwide in 2023 is estimated to be USD 240 billion2
1 World Cancer Research Fund
2 Global Oncology Trends 2019 – Therapeutics, Clinical Development and Health System Implications. IQVIA Institute for Human Data Science.